{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:02Z","timestamp":1740144062073,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"LEO Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40261-017-0608-y","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T13:13:38Z","timestamp":1512393218000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics and Safety of Ingenol Disoxate Gel Administered Under Maximum-Use Conditions to Patients With Actinic Keratosis"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct02424305","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1251","authenticated-orcid":false,"given":"Edward","family":"Lain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"Skov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,4]]},"reference":[{"issue":"1 Suppl 1","key":"608_CR1","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jaad.2012.10.001","volume":"68","author":"DS Rigel","year":"2013","unstructured":"Rigel DS, Stein Gold LF. The importance of early diagnosis and treatment of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S20\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"608_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1067\/mjd.2000.103339","volume":"42","author":"RG Glogau","year":"2000","unstructured":"Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1):S23\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 1","key":"608_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.12833","volume":"29","author":"J Malvehy","year":"2015","unstructured":"Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol. 2015;29(Suppl 1):3\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1 Suppl 1","key":"608_CR4","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2012.09.051","volume":"68","author":"RI Ceilley","year":"2013","unstructured":"Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S28\u201338.","journal-title":"J Am Acad Dermatol"},{"unstructured":"LEO Pharma. Picato\u00ae (ingenol mebutate) gel, 0.015%, 0.05%. Prescribing information. 2015 [cited 10 August 2015]; https:\/\/www.picato.com\/_pdf\/PrescribingInformation.pdf. Accessed 20 Feb 2017.","key":"608_CR5"},{"issue":"11","key":"608_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"608_CR7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13555-016-0137-2","volume":"6","author":"M Bertelsen","year":"2016","unstructured":"Bertelsen M, Stahlhut M, Grue-Sorensen G, Liang X, Christensen GB, Skak K, et al. Ingenol disoxate: a novel 4-isoxazolecarboxylate ester of ingenol with improved properties for treatment of actinic keratosis and other non-melanoma skin cancers. Dermatol Ther (Heidelb). 2016;6(4):599\u2013626.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"608_CR8","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/09546634.2017.1303568","volume":"28","author":"M Bourcier","year":"2017","unstructured":"Bourcier M, Stein Gold L, Guenther L, Andreassen CM, Selmer J, Goldenberg G. A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250\u00a0cm2 on the chest. J Dermatol Treat. 2017;28(7):652\u20138.","journal-title":"J Dermatol Treat."},{"issue":"6","key":"608_CR9","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/bjd.15304","volume":"176","author":"J Weiss","year":"2017","unstructured":"Weiss J, Ulrich M, Bukhalo M, Osterdal ML, Bang B, Hanke CW. A seamless phase I\/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. Br J Dermatol. 2017;176(6):1456\u201364.","journal-title":"Br J Dermatol"},{"issue":"2","key":"608_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13555-014-0059-9","volume":"4","author":"R Rosen","year":"2014","unstructured":"Rosen R, Marmur E, Anderson L, Welburn P, Katsamas J. A new, objective, quantitative scale for measuring local skin responses following topical actinic keratosis therapy with ingenol mebutate. Dermatol Ther (Heidelb). 2014;4(2):207\u201319.","journal-title":"Dermatol Ther (Heidelb)."},{"doi-asserted-by":"publisher","unstructured":"Bucko AD, Jarratt M, Stough DB, Kyhl L, Villumsen J, Hall A. Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas. J Dermatolog Treat. Epub 25 May 2017. https:\/\/doi.org\/10.1080\/09546634.2017.1329506.","key":"608_CR11","DOI":"10.1080\/09546634.2017.1329506"},{"unstructured":"Anderson L, Jarrett M, Schmieder G, Schumack S, Katsamas J, Welburn P. Tolerability and pharmacokinetics of ingenol mebutate 0.05% gel applied to treatment areas up to 100\u00a0cm2 on the forearm(s) of patients with actinic keratosis. J Clin Aesthet Dermatol. 2014;7(12):19\u201329.","key":"608_CR12"},{"key":"608_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/ijd.12840","volume":"54","author":"E Stockfleth","year":"2015","unstructured":"Stockfleth E, Peris K, Guillen C, Cerio R, Basset-Seguin N, Foley P, et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol. 2015;54:509\u201315.","journal-title":"Int J Dermatol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-017-0608-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0608-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0608-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:41:26Z","timestamp":1628617286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-017-0608-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0608-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"type":"print","value":"1173-2563"},{"type":"electronic","value":"1179-1918"}],"subject":[],"published":{"date-parts":[[2017,12,4]]},"assertion":[{"value":"4 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical trial protocol and any relevant amendments to the clinical trial protocol were approved by\/received favorable opinion from the relevant Institutional Review Boards prior to the enrolment of patients. This clinical trial was conducted in accordance with the revision, current at the start of the trial, of the World Medical Association\u2019s Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Edward Lain has received consulting fees or honorarium from LEO Pharma and Gage Pharmaceuticals. Torsten Skov and Anders Hall are employees of LEO Pharma A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients received written and verbal information regarding the clinical trial. The patient\u2019s signed and dated informed consent to participate in the clinical trial was obtained prior to any trial-related activities being carried out in accordance with the International Conference on Harmonization.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was funded by LEO Pharma.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LEO Pharma was involved in the design and conduct of the trial; collection, management, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the sponsor"}}]}}